// App-Quantinova.ai

4339 : Prognostic significance of copy number alteration burden in unfavorable intermediate-risk prostate cancers harboring intraductal carcinoma and cribriform architecture

Researchers

Presenter

  • Melvin Lee Kiang Chua

Principal Investigators

  • Melania Pintilie

  • Emilie Lalonde

  • Charlotte Kweldam

  • Winnie Lo

  • Alejandro Berlin

  • Alan Dal Pra

  • Michele Orain

  • Valerie Picard

  • Helene Hovington

  • Alain Begeron

  • Yves Fradet

  • Bernard Tetu

  • Julie Livingstone

  • Alice Meng

  • Jun Yan Zhang

  • Gaetano Zafarana

  • Neil Fleshner

  • Mike Fraser

  • Paul Boutros

  • Robert Bristow

  • Theodorus van der Kwast

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Ontario Institute for Cancer Research, Toronto, ON, Canada

  • Erasmus MC, Rotterdam, Netherlands

  • Universite Laval, Quebec City, Quebec, Canada.

  • University Health Network, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Breast cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved